Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

ClinicalTrials.gov ID: NCT03976401

Public ClinicalTrials.gov record NCT03976401. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Nonalcoholic Steatohepatitis (NASH)

Study identification

NCT ID
NCT03976401
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Akero Therapeutics, Inc
Industry
Enrollment
110 participants

Conditions and interventions

Interventions

  • EFX Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 27, 2019
Primary completion
Feb 9, 2021
Completion
Jan 9, 2022
Last update posted
Aug 3, 2022

2019 – 2022

United States locations

U.S. sites
26
U.S. states
9
U.S. cities
24
Facility City State ZIP Site status
Akero Clinical Study Site Tucson Arizona 85711
Akero Clinical Study Site Little Rock Arkansas 72117
Akero Clinical Study Site Huntington Park California 90255
Akero Clinical Study Site Los Angeles California 90036
Akero Clinical Study Site Los Angeles California 90057
Akero Clinical Study Site Panorama City California 91402
Akero Clinical Study Site Poway California 92064
Akero Clinical Study Site Boca Raton Florida 33434
Akero Clinical Study Site Lakewood Rch Florida 34211
Akero Clinical Study Site Miami Florida 33156
Akero Clinical Study Site New Port Richey Florida 34653
Akero Clinical Study Site Ocoee Florida 34761
Akero Clinical Study Site Port Orange Florida 32127
Akero Clinical Study Site Sarasota Florida 34240
Akero Clinical Study Site Baton Rouge Louisiana 70809
Akero Clinical Study Site Marrero Louisiana 70072
Akero Clinical Study Site Kansas City Missouri 64131
Akero Clinical Study Site Berlin New Jersey 08009
Akero Clinical Study Site Chattanooga Tennessee 37421
Akero Clinical Study Site Cedar Park Texas 78613
Akero Clinical Study Site Dallas Texas 75246
Akero Clinical Study Site Edinburg Texas 78539
Akero Clinical Study Site Fort Worth Texas 76104
Akero Clinical Study Site San Antonio Texas 78215
Akero Clinical Study Site San Antonio Texas 78229
Akero Clinical Study Site Webster Texas 77598

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03976401, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 3, 2022 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03976401 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →